奥沙利铂联合替吉奥方案二线治疗转移性胰腺癌的疗效观察

目的观察奥沙利铂联合替吉奥方案二线治疗转移性胰腺癌的疗效。方法对我院2010年8月一2012年6月收治的晚期胰腺癌患者24例，给予奥沙利铂联合替吉奥化疗，奥沙利铂130mg／m。静脉滴注第1天；替吉奥40mg／m^2口服，每天2次，第1～14天，每3周重复，治疗2个周期后进行疗效评价。结果部分缓解3例（12．50％），稳定7例（29．17％），进展14例（58．33％），疾病控制率为41．67％（10／24），中位生存期为4．6个月。主要的不良反应有中性粒细胞减少、血小板减少、恶心呕吐等，大多为1—2级毒性，经对症支持治疗后好转。结论奥沙利铂联合替吉奥作为二线治疗晚期胰腺癌有较好的疗效，不良反应患者大多可耐受。

Observation of curative effect of oxaliplatin combined with S-1 second-line treatment in patients with metastatic pan-creatic cancer

Objective To observe the effects and safety of oxaliplatin combined with S-I second-line treatment in pa- tients with metastatic pancreatic cancer. Methods 24 patients with metastatic pancreatic cancer were chosen from August 2010 to June 2012 in our hospital.. The patients were treated with oxaliplatin combined with S-1 ,oxaliplatin 130mg/m^2 intra- venous infusion on day 1, S-1 capsule 40mg/m^2 ,bid,from dl-14,with a cycle of every 3 weeks. Evaluated the efficacy after two cycles of treatment. Results The response rate of patients was as follows： partial remission occurred in 3 cases （ 12. 50% ） ,no change in 7cases （29. 17% ） and progression of disease in 14 cases （58.33%）. disease control rate was 41.67% （10/24）. The median survival time was 4.6 months. Conclusion The combination of oxaliplatin and S-1 second- line chemotherapy appears to be a beneficial treatment in patients with metastatic pancreatic cancer.